ORENCIA™ (Abatacept- generic name), manufactured by Bristol-Myer Squibb, is indicated for reducing the signs and symptoms, inducing major clinical response, slowing disease progression of structural damage, and improving physical function in people with moderate to severe Rheumatoid Arthritis (RA), who have had an inadequate response to one or more DMARDS, such as methotrexate or TNF antagonists. ORENCIA™ (abatacept) can be given as monotherapy or with other RA medications called DMARDs.
Prescribing Information
ORENCIA™ (abatacept) is administered as a 30 min IV infusion at 0, 2, and 4 weeks, then every 4 weeks thereafter. ORENCIA™ (abatacept) should not be used in combination with the TNF antagonists or another injectable medication called Kineret (anakinra) for RA. For more detailed prescribing information please refer to the ORENCIA™ (abatacept) Physician Prescribing Information.